These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 37037948)
1. Pen-administered low-dose dasiglucagon vs usual care for prevention and treatment of non-severe hypoglycaemia in people with type 1 diabetes during free-living conditions: a Phase II, randomised, open-label, two-period crossover trial. Laugesen C; Ranjan AG; Schmidt S; Nørgaard K Diabetologia; 2023 Jul; 66(7):1208-1217. PubMed ID: 37037948 [TBL] [Abstract][Full Text] [Related]
2. Impact of flash glucose monitoring on hypoglycaemia in adults with type 1 diabetes managed with multiple daily injection therapy: a pre-specified subgroup analysis of the IMPACT randomised controlled trial. Oskarsson P; Antuna R; Geelhoed-Duijvestijn P; Krӧger J; Weitgasser R; Bolinder J Diabetologia; 2018 Mar; 61(3):539-550. PubMed ID: 29273897 [TBL] [Abstract][Full Text] [Related]
3. Day-and-night glycaemic control with closed-loop insulin delivery versus conventional insulin pump therapy in free-living adults with well controlled type 1 diabetes: an open-label, randomised, crossover study. Bally L; Thabit H; Kojzar H; Mader JK; Qerimi-Hyseni J; Hartnell S; Tauschmann M; Allen JM; Wilinska ME; Pieber TR; Evans ML; Hovorka R Lancet Diabetes Endocrinol; 2017 Apr; 5(4):261-270. PubMed ID: 28094136 [TBL] [Abstract][Full Text] [Related]
4. Hypoglycaemia frequency and physiological response after double or triple doses of once-weekly insulin icodec vs once-daily insulin glargine U100 in type 2 diabetes: a randomised crossover trial. Pieber TR; Arfelt KN; Cailleteau R; Hart M; Kar S; Mursic I; Svehlikova E; Urschitz M; Haahr H Diabetologia; 2023 Aug; 66(8):1413-1430. PubMed ID: 37308751 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemia-prone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial. Bosi E; Choudhary P; de Valk HW; Lablanche S; Castañeda J; de Portu S; Da Silva J; Ré R; Vorrink-de Groot L; Shin J; Kaufman FR; Cohen O; Lancet Diabetes Endocrinol; 2019 Jun; 7(6):462-472. PubMed ID: 31047902 [TBL] [Abstract][Full Text] [Related]
6. Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitus. Hövelmann U; Olsen MB; Mouritzen U; Lamers D; Kronshage B; Heise T Diabetes Obes Metab; 2019 Mar; 21(3):601-610. PubMed ID: 30350477 [TBL] [Abstract][Full Text] [Related]
7. Flexible insulin therapy with a hybrid regimen of insulin degludec and continuous subcutaneous insulin infusion with pump suspension before exercise in physically active adults with type 1 diabetes (FIT Untethered): a single-centre, open-label, proof-of-concept, randomised crossover trial. Aronson R; Li A; Brown RE; McGaugh S; Riddell MC Lancet Diabetes Endocrinol; 2020 Jun; 8(6):511-523. PubMed ID: 32445738 [TBL] [Abstract][Full Text] [Related]
8. Low-Dose Dasiglucagon Versus Oral Glucose for Prevention of Insulin-Induced Hypoglycemia in People With Type 1 Diabetes: A Phase 2, Randomized, Three-Arm Crossover Study. Laugesen C; Ranjan AG; Schmidt S; Nørgaard K Diabetes Care; 2022 Jun; 45(6):1391-1399. PubMed ID: 35475907 [TBL] [Abstract][Full Text] [Related]
9. Dasiglucagon, a next-generation glucagon analogue, for treatment of severe hypoglycaemia via an autoinjector device: Results of a phase 3, randomized, double-blind trial. Bailey TS; Willard J; Klaff LJ; Yager Stone J; Melgaard A; Tehranchi R Diabetes Obes Metab; 2021 Oct; 23(10):2329-2335. PubMed ID: 34169625 [TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 study. Frias J; Chien J; Zhang Q; Chigutsa E; Landschulz W; Syring K; Wullenweber P; Haupt A; Kazda C Lancet Diabetes Endocrinol; 2023 Mar; 11(3):158-168. PubMed ID: 36758572 [TBL] [Abstract][Full Text] [Related]
12. Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial. van Beers CA; DeVries JH; Kleijer SJ; Smits MM; Geelhoed-Duijvestijn PH; Kramer MH; Diamant M; Snoek FJ; Serné EH Lancet Diabetes Endocrinol; 2016 Nov; 4(11):893-902. PubMed ID: 27641781 [TBL] [Abstract][Full Text] [Related]
13. Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial. Heinemann L; Freckmann G; Ehrmann D; Faber-Heinemann G; Guerra S; Waldenmaier D; Hermanns N Lancet; 2018 Apr; 391(10128):1367-1377. PubMed ID: 29459019 [TBL] [Abstract][Full Text] [Related]
14. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients. Lo C; Jun M; Badve SV; Pilmore H; White SL; Hawley C; Cass A; Perkovic V; Zoungas S Cochrane Database Syst Rev; 2017 Feb; 2(2):CD009966. PubMed ID: 28238223 [TBL] [Abstract][Full Text] [Related]
15. 2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial. Kropff J; Del Favero S; Place J; Toffanin C; Visentin R; Monaro M; Messori M; Di Palma F; Lanzola G; Farret A; Boscari F; Galasso S; Magni P; Avogaro A; Keith-Hynes P; Kovatchev BP; Bruttomesso D; Cobelli C; DeVries JH; Renard E; Magni L; Lancet Diabetes Endocrinol; 2015 Dec; 3(12):939-47. PubMed ID: 26432775 [TBL] [Abstract][Full Text] [Related]
16. Effect of insulin analogues on risk of severe hypoglycaemia in patients with type 1 diabetes prone to recurrent severe hypoglycaemia (HypoAna trial): a prospective, randomised, open-label, blinded-endpoint crossover trial. Pedersen-Bjergaard U; Kristensen PL; Beck-Nielsen H; Nørgaard K; Perrild H; Christiansen JS; Jensen T; Hougaard P; Parving HH; Thorsteinsson B; Tarnow L Lancet Diabetes Endocrinol; 2014 Jul; 2(7):553-61. PubMed ID: 24794703 [TBL] [Abstract][Full Text] [Related]
17. Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: a randomised crossover trial. Russell SJ; Hillard MA; Balliro C; Magyar KL; Selagamsetty R; Sinha M; Grennan K; Mondesir D; Ekhlaspour L; Zheng H; Damiano ER; El-Khatib FH Lancet Diabetes Endocrinol; 2016 Mar; 4(3):233-243. PubMed ID: 26850709 [TBL] [Abstract][Full Text] [Related]
18. Breastfeeding at night is rarely followed by hypoglycaemia in women with type 1 diabetes using carbohydrate counting and flexible insulin therapy. Ringholm L; Roskjær AB; Engberg S; Andersen HU; Secher AL; Damm P; Mathiesen ER Diabetologia; 2019 Mar; 62(3):387-398. PubMed ID: 30607466 [TBL] [Abstract][Full Text] [Related]
19. Integrated safety and efficacy analysis of dasiglucagon for the treatment of severe hypoglycaemia in individuals with type 1 diabetes. Heller S; Battelino T; Bailey TS; Pieber TR; Hövelmann U; Plum-Mörschel L; Melgaard AE; Aronson R; DiMeglio LA; Johansen T; Danne T Diabetes Obes Metab; 2023 May; 25(5):1351-1360. PubMed ID: 36692230 [TBL] [Abstract][Full Text] [Related]
20. Weight-based carbohydrate treatment of hypoglycaemia in people with Type 1 diabetes using insulin pump therapy: a randomized crossover clinical trial. McTavish L; Corley B; Weatherall M; Wiltshire E; Krebs JD Diabet Med; 2018 Mar; 35(3):339-346. PubMed ID: 29285796 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]